Medicare part D and long-term care: A systematic review of quantitative and qualitative evidence

Drugs and Aging

Volumn 30, Issue 9, 2013, Pages 701-720

  Pimentel, Camilla B ^a   Lapane, Kate L ^a   Briesacher, Becky A ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

DRUG USE; DRUG UTILIZATION; LONG TERM CARE; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

EVIDENCE-BASED MEDICINE; HUMANS; LONG-TERM CARE; MEDICARE PART D; OUTCOME ASSESSMENT (HEALTH CARE); PRESCRIPTION DRUGS; UNITED STATES;

EID: 84883277306     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0096-6     Document Type: Review

References (48)

1. The Henry J. Kaiser Family Foundation. Medicare: a primer. Menlo Park: The Henry J. Kaiser Family Foundation; 2010. Report no.: 7615-03.
2. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, HR 1/Pub. L. No. 108-173, 117 Stat. 2066 (2003).
3. Edelman TS. Medicare prescription drug coverage for residents of nursing homes and assisted living facilities: special problems and concerns. Washington, DC: The Henry J. Kaiser Family Foundation; 2005. Report no.: 7342.
4. Harrington C, Carrillo H, Blank BW, et al. Nursing facilities, staffing, residents and facilities deficiencies, 2004 through 2009 [online]. http://www.pascenter.org/documents/OSCAR-complete-2010.pdf. Accessed 14 Oct 2012.
5. Stuart B, Simoni-Wastila L, Baysac F, et al. Coverage and use of prescription drugs in nursing homes: implications for the Medicare Modernization Act. Med Care. 2006;44(3):243-9.
6. Avorn J, Gurwitz JH. Drug use in the nursing home. Ann Intern Med. 1995;123(3):195-204.
7. Jones AL, Dwyer LL, Bercovitz AR, et al. The National Nursing Home Survey: 2004 overview. Vital Health Stat 13. 2009;(167):1-155.
8. Hing E, Bloom B. Long-term care for the functionally dependent elderly. Vital Health Stat 13. 1990;(104):1-50.
9. Requirements for States and Long Term Care Facilities, 42 C.F.R § 483.60 (2006).
10. The Henry J. Kaiser Family Foundation. Distribution of certified nursing facility residents by primary payer source, 2010 [online]. http://www. statehealthfacts.org/comparebar.jsp?ind=410&cat=8. Accessed 18 Jan 2013.
11. US Centers for Medicare and Medicaid Services. Medicare prescription drug benefit manual, Chapter 6 - Part D Drugs and Formulary Requirements [online]. http://www.cms.gov/Medicare/Prescription-Drug-Coverage/ PrescriptionDrugCovContra/downloads/Chapter6.pdf. Accessed 1 Dec 2012.
12. Voluntary Medicare Prescription Drug Benefit, 42 C.F.R § 423.782 (2005).
13. Lau DT, Briesacher BA, Touchette DR, et al. Medicare Part D and quality of prescription medication use in older adults. Drugs Aging. 2011;28(10):797-807.
14. Polinski JM, Donohue JM, Kilabuk E, et al. Medicare Part D's effect on the under- and overuse of medications: a systematic review. J Am Geriatr Soc. 2011;59(10):1922-33.
15. Polinski JM, Kilabuk E, Schneeweiss S, et al. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc. 2010;58(9):1764-79.
16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
17. Lohr KN, Carey TS. Assessing "best evidence": issues in grading the quality of studies for systematic reviews. Jt Comm J Qual Improv. 1999;25(9):470-9.
18. Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers' Handbook 4.2.2 [updated March 2004]. The Cochrane Library, Issue 1. Chichester: Wiley; 2004.
19. Moher D, Cook DJ, Jadad AR, et al. Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999;3(12):i-iv 1-98.
20. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-84.
21. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-57.
22. Stevenson DG, Huskamp HA, Newhouse JP. Medicare Part D, nursing homes, and long-term care pharmacies. Washington, DC: Medicare Payment Advisory Commission; 2007. Report no.: 07-2.
23. Stevenson DG, Huskamp HA, Newhouse JP. Medicare Part D and the nursing home setting. Gerontologist. 2008;48(4):432-41.
24. Bazalo G, Weiss R. Measurement of unused medication in Medicare Part D residents in skilled nursing facilities. Consult Pharm. 2011;26(9):647-56.
25. Bazalo G, Weiss RC. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing. Consult Pharm. 2012;27(4):269-73.
26. US Department of Health and Human Services, Office of Inspector General. Availability of Medicare Part D drugs to dual-eligible nursing home residents. Washington, DC: US Department of Health and Human Services, 2008 Jun. Report no.: OEI-02-06-00190.
27. US Department of Health and Human Services, Office of Inspector General. Role of nursing homes and long term care pharmacies in assisting dual-eligible residents with selecting Part D plans. Washington, DC: US Department of Health and Human Services, 2008 Jun. Memorandum report no.: OEI-02-06-00191.
28. Briesacher BA, Soumerai SB, Field TS, et al. Nursing home residents and enrollment in Medicare Part D. J Am Geriatr Soc. 2009;57(10):1902-7.
29. Briesacher BA, Soumerai SB, Field TS, et al. Medicare Part D's exclusion of benzodiazepines and fracture risk in nursing homes. Arch Intern Med. 2010;170(8):693-8.
30. Golden AG, Qiu D, Roos BA. Medication assessments by care managers reveal potential safety issues in homebound older adults. Ann Pharmacother. 2011;45(4):492-8.
31. Huskamp HA, Stevenson DG, Keating NL, et al. Rejections of drug claims for nursing home residents under Medicare Part D. Health Aff (Millwood). 2008;27(2):560-7.
32. Stevenson DG, Huskamp HA, Keating NL, et al. Medicare Part D and nursing home residents. J Am Geriatr Soc. 2007;55(7):1115-25.
33. Stevenson DG, Keohane LM, Mitchell SL, et al. Medicare Part D claims rejections for nursing home residents, 2006 to 2010. Am J Manag Care. 2012;18(10):647-54.
34. West JC, Wilk JE, Rae DS, et al. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients. J Clin Psychiatry. 2010;71(4):400-10.
35. Wilk JE, West JC, Rae DS, et al. Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients. Psychiatr Serv. 2008;59(1):34-9.
36. Cote BR, Petersen EA. Impact of therapeutic switching in long-term care. Am J Manag Care. 2008;14(11 Suppl):SP23-8.
37. Raehl C, Maclaughlin E, Patry R, et al. Early implementation of Medicare Part D in urban and rural nursing facilities. Consult Pharm. 2007;22(9):744-53.
38. Centers for Medicare and Medicaid Services. Impact of reassignment in the Part D program on health outcomes. Baltimore: Centers for Medicare and Medicaid Services; 2009.
39. US Government Accountability Office. Medicare Part D: challenges in enrolling new dual-eligible beneficiaries. Washington, DC: US Government Accountability Office; 2007. Report no.: GAO-07-272.
40. US Government Accountability Office. Many factors, including administrative challenges, affect access to Part D vaccinations. Washington, DC: US Government Accountability Office; 2011. Report no.: GAO-12-61.
41. Huskamp HA, Oakman TS, Stevenson DG. Medicare Part D and its impact in the nursing home sector: an update. Washington, DC: Medicare Payment Advisory Commission; 2010. Report no.: 10-4.
42. Buchsbaum L, Varon J, Kagel E, et al. Perspectives on Medicare Part D and dual eligibles: key informants' views from three states. Menlo Park, CA: The Henry K. Kaiser Family Foundation; 2007. Report no.: 7639.
43. Jung C. Impact of Medicare Part-D on generic drug utilization in the long-term care facilities [online]. http://www.heinz.cmu.edu/research/377full. pdf. Accessed 18 Jan 2013.
44. The Henry J. Kaiser Family Foundation. Medicare Part D prescription drug plan [PDP] availability in 2013. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2012. Publication no. 7426-09.
45. Voluntary Medicare Prescription Drug Benefit, 42 C.F.R § 423.32; 2005.
46. US Centers for Medicare and Medicaid Services, Survey and Certification Group. Nursing homes and Medicare Part D. Baltimore, MD: US Centers for Medicare and Medicaid Services; 2006. Memorandum reference no.: S&C-06-16.
47. US Centers for Medicare and Medicaid Services. CMS guide to requests for Medicare Part D Prescription Drug Event (PDE) data [online]. Baltimore, MD: US Centers for Medicare and Medicaid Services, 2008 Aug 15. http://www.cms.gov/ Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/downloads/ GuidePartDDataRequests.pdf. Accessed 18 Nov 2012.
48. Caffrey C, Sengupta M, Park-Lee E, et al. Residents living in residential care facilities: United States, 2010. NCHS Data Brief. 2012;91:1-8.